Measles, mumps and rubella vaccine, autism and inflammatory bowel disease: Advising concerned parents

Pediatric Drugs

Volumn 4, Issue 10, 2002, Pages 631-635

  Elliman, D A C ^a   Bedford, H E ^b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; RUBELLA VACCINE;

AUTISM; DRUG APPROVAL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; ENTERITIS; EVIDENCE BASED MEDICINE; HISTORY; HUMAN; MEASLES; MUMPS; PARENT COUNSELING; PRIORITY JOURNAL; REVIEW; RUBELLA;

EID: 0036396374     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200204100-00001     Document Type: Review

References (35)

1. Data on file, Office for National Statistics, 2002
2. Data on file. Communicable Disease Surveillance Centres, 2002
3. Groseclose SL, Hall PA. Knowles CM, et al., on behalf of CDC. Summary of notifiable diseases, United States, 1999. MMWR Morb Mortal Wkly Rep 2001; 48 (53): 1-104
4. Bottiger M, Christenson B, Taranger J. et al. Mass vaccination programme aimed at eradicating measles, mumps and rubella in Sweden: vaccination of school children. Vaccine 1983; 3: 113-6
5. Plotkin S, Wharton M. Mumps vaccine. In: Plotkin S. Orenstein W, editors. Vaccines. Philadelphia (PA): WB Saunders Company. 1999; 267-92
6. King GE, Markowitz LE. Patricia PA, et al. Clinical efficacy of measles vaccine during the 1990 measles epidemic. Pediatr Infect Dis J 1991; 10: 883-7
7. Department of Vaccines and Biologicats. WHO vaccine preventable diseases: monitoring system. 2000 global summary. Geneva: World Health Organization, 2000
8. Peltola H, Heinonen OP, Valle M. et al. The elimination of indigenous measles, mumps and rubella from Finland by a 12-year, two dose vaccination program. N Engl J Med 1994; 331: 1397-402
9. Wakefield AJ, Montgomery SM. Measles mumps rubella vaccine: through a glass darkly. Adverse Drug React Toxicol Rev 2000; 19: 265-83
10. Combined measles, mumps and rubella vaccines: response of the Medicines Control Agency and Department of Health to issues raised in papers published in Adverse Drug Reactions and Toxicological Reviews, Vol. 19, No. 4, 2000. London: Department of Health, 2001
11. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine: a double-blind placebo-controlled trial in twins. Lancet 1986; 1: 939-42
12. Ekbom A, Wakefield AJ, Zack M. et al. Perinatal measles infection and subsequent Crohn's disease. Lancet 1994; 344: 508-10
13. Thompson NP, Montgomery SM, Pounder RE. et al. Is measles vaccination a risk factor for inflammatory bowel disease. Lancet 1995; 345: 1071-4
14. Nielsen LL, Nielsen NM, Melbye M, et al. Exposure to measles in utero and Crohn's disease: Danish register study. BMJ 1998; 316 (7126): 196-7
15. Feeney MCA. Winwood P. Snook J, for the East Dorset Gastroenterology Group. A case-control study of measles vaccination and inflammatory bowel disease. Lancet 1997; 350: 764-6
16. Chadwick N, Bruce IJ, Schepelmann S. et al. Measles virus DNA is not identified in inflammatory bowel disease using hybrid capture and reverse transcriptase followed by polymerase chain reaction. J Med Virol 1998; 55: 305-11
17. Davis RL. Kramarz P, Bohlke K, et al. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease. Arch Pediatr Adolesc Med 2001; 155: 354-9
18. Wakefield AJ. Murch SH, Anthony A, et al. Ileal-lymphoid nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998; 351: 1327-8
19. Chen RT, DeStefano F. Vaccine adverse events: causal or coincidental. Lancet 1998; 351: 611-2
20. Gilberg C, Hleijbel H. MMR and autism. Autism 1998; 2: 423-4
21. Taylor B, Miller E, Farrington CP, et al. Autism and measles, mumps and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999; 353: 2026-9
22. Spitzer WO. A sixty day war of words: is MMR linked to autism [letter]. Adverse Drug React Toxicol Rev 2001; 20: 47-55
23. Farrington CP, Miller E, Taylor B. MMR and autism: further evidence against a causal association. Vaccine 2001; 19: 3632-5
24. Fombonne E, Chakrabarti S. No evidence for a new variant of measles-mumps rubella-induced autism. Pediatrics 2001; 108 (4): E58
25. Taylor B, Miller E, Lingam R, et al. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ 2002; 324: 393-6
26. Halsey N, Hyman SL, and the Conference Writing Panel. Measles-mumps-rubella vaccine and the autistic spectrum disorder: report from the New Challenges in Childhood Immunizations Conference convened in Oak Brook, Illinois, June 12-13 2000. Pediatrics 2001; 107: E84
27. Stratton K, Gable A, Shetty P, et al., editors. Immunization safety review: measles-mumps-rubella vaccine and autism. The Immunization Safety Review Committee, Institute of Medicine. Washington, DC: National Academy Press, 2001
28. Ghosh S, Armitage E, Wilson D, et al. Detection of persistent measles virus infection in Crohn's disease: current status of experimental work. Gut 2001; 48: 748-52
29. Wakefield AJ. Testimony before Congressional Oversight Committee on Autism and Immunisation, April 6 2000 [online]. Available from URL: http://www.gpo.gov/ congress/house [Accessed 2002 Jul 23]
30. Miller E, Goldacre M, Pugh S, et al. Risk of aseptic meningitis after measles, mumps and rubella vaccine in UK children. Lancet 1993; 341: 979-82
31. Davidkin I, Peltola H, Leinikki PMV. Duration of immunity induced by two-dose measles, mumps and rubella (MMR) vaccination: a 15-year follow-up in Finland. Vaccine 2000; 18: 3106-12
32. Ramsay M, Gay N, Miller E, et al. The epidemiology of measles in England and Wales: rationale for the 1994 national vaccination campaign. Commun Dis Rep CDR Rev 1994; 4: R141-6
33. Schlegel M, Osterwalder JJ, Galeazzi RL, et al. Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study [published erratum appears in BMJ 1999; 319 (7208): 477]. BMJ 1999; 319: 352
34. Uhlmann V, Martin CM. Sheils O, et al. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. Mol Pathol 2002; 55: 84-90
35. Morris A, Aldulaimi D. New evidence for a viral pathogenic mechanism for new variant inflammatory bowel disease and development disorder [comment]. Mol Pathol 2002; 55: 83